In one study using the human prostate cancer cell line, LNCaP, it was demonstrated that treatment with brefeldin A, a pharmacological compound that collapses the ER and Golgi to a single compartment, levels of full-length CREB3L4 were reduced, indicating that CREB3L4 undergoes S1P and S2P cleavage at the Golgi [55]. Here, CREB3L4 is linked to prostate cancer.